Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Section 4 of 6

Clinical evidence

587 evidence topics · 82 sources

Study summaries

ABTECT-1

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by arm in the posted results
PopulationABX464 50 mgABX464 25 mgPlaceboTotal
Started“318”“161”“160”Not reported
Baseline (Full Analysis Set)“318”“160”“158”“636”
Primary and secondary endpoints (Full Analysis Set)“318”“160”“158”Not reported
Adverse events (at risk)“0/318 (0.00%)”“0/160 (0.00%)”“0/158 (0.00%)”Not reported
Description of analysis sets
Results
Participant disposition
Participant flow by arm in the posted results
DispositionABX464 50 mgABX464 25 mgPlacebo
Started“318”“161”“160”
Completed“291”“155”“143”
Not completed“27”“6”“17”
Adverse event“18”“0”“6”
Lost to follow-up“1”“1”“1”
Never dosed“0”“1”“1”
Non-compliance with study drug“2”“0”“0”
Physician decision“1”“0”“1”
Protocol violation“1”“0”“1”
Withdrawal by subject“4”“4”“7”
Pooled ABTECT-1 and ABTECT-2: study discontinuation and reasons
DispositionObefazimod 50 mgObefazimod 25 mgPlacebo
Participants who discontinued the study, n (%)“54 (8.5)”“23 (7.2)”“31 (9.7)”
Adverse event, n (% of discontinuations)“31 (57.4)”“8 (34.8)”“14 (45.2)”
Withdrawal by subject“13 (24.1)”“10 (43.5)”“10 (32.3)”
Lack of efficacy“2 (3.7)”“2 (8.7)”“1 (3.2)”
Lost to follow-up“4 (7.4)”“1 (4.3)”“1 (3.2)”
Baseline characteristics
Baseline characteristics by arm in the posted results
CharacteristicABX464 50 mg (n=318)ABX464 25 mg (n=160)Placebo (n=158)Total (n=636)
Age, years, mean (SD)“42.7(14.3)”“41.5(13.54)”“43.1(13.59)”“42.5(13.93)”
Age 65 years or older, participants“25”“12”“11”“48”
Female, participants“129”“56”“66”“251”
Male, participants“189”“104”“92”“385”
Asian, participants“87”“34”“45”“166”
Black or African American, participants“5”“3”“2”“10”
White, participants“219”“114”“106”“439”
Weight, kg, mean (SD)“72.41(18.581)”“72.58(17.269)”“71.28(16.392)”“72.17(17.713)”
Duration of ulcerative colitis, years, mean (SD)“7.98(7.348)”“7.8(7.151)”“7.51(7.761)”“7.82(7.395)”
At least one prior advanced therapy inadequate response, participants“149”“70”“69”“288”
Inadequate response to JAK inhibitors among those with AT-IR, participants“22”“15”“15”“52”
Modified Mayo Score, mean (SD)“6.9(1.06)”“6.8(1.04)”“6.9(1.04)”“6.9(1.05)”
Mayo endoscopic subscore 2, participants“128”“69”“64”“261”
Mayo endoscopic subscore 3, participants“190”“91”“94”“375”
Fecal calprotectin, µg/g, mean (SD)“3768.46(6219.12)”“2533.58(3761.06)”“5390.53(9479.94)”“3828.77(6729.81)”
Pooled ABTECT-1 and ABTECT-2: treatment exposure
ExposureObefazimod 50 mg (n=636)Obefazimod 25 mg (n=319)Placebo (n=317)
Duration of exposure, days, mean (SD)“58.8 (12.62)”“59.5 (11.14)”“58.7 (11.14)”
Duration of exposure, days, median [min, max]“60.0 [1, 106]”“61.0 [4, 96]”“61.0 [5, 102]”
Efficacy results
Primary and key secondary endpoints at Week 8
Endpoint at Week 8, % (n)Placebo (N=158)Obefazimod 25 mg (N=160)Obefazimod 50 mg (N=318)25 mg minus placebo, %25 mg p-value50 mg minus placebo, %50 mg p-value
Clinical remission (primary)“2.5 (4)”View highlighted excerpt for this quote“23.8 (38)”View highlighted excerpt for this quote“21.7 (69)”View highlighted excerpt for this quote“21.4”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“19.3”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Clinical response“28.5 (45)”View highlighted excerpt for this quote“65.6 (105)”View highlighted excerpt for this quote“61.0 (194)”View highlighted excerpt for this quote“37.2”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“32.6”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Endoscopic improvement“5.7 (9)”View highlighted excerpt for this quote“37.5 (60)”View highlighted excerpt for this quote“33.3 (106)”View highlighted excerpt for this quote“32.0”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“27.8”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
HEMI“3.2 (5)”View highlighted excerpt for this quote“23.8 (38)”View highlighted excerpt for this quote“23.0 (73)”View highlighted excerpt for this quote“20.7”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“20.0”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Symptomatic remission“17.7 (28)”View highlighted excerpt for this quote“42.5 (68)”View highlighted excerpt for this quote“41.2 (131)”View highlighted excerpt for this quote“24.9”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“23.7”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Participants meeting each endpoint at Week 8 in the posted results
Endpoint at Week 8, participantsABX464 50 mg (n=318)ABX464 25 mg (n=160)Placebo (n=158)
Clinical remission per modified Mayo Score (primary)“69”“38”“4”
Endoscopic improvement“106”“60”“9”
Clinical response per modified Mayo Score“194”“105”“45”
HEMI per Geboes“73”“38”“5”
Pooled ABTECT-1 and ABTECT-2: primary and secondary endpoints at Week 8
Endpoint at Week 8, % (n)Placebo (N=317)Obefazimod 25 mg (N=319)Obefazimod 50 mg (N=636)25 mg minus placebo, %50 mg minus placebo, %
Clinical remission“4.4 (14)”View highlighted excerpt for this quote“17.6 (56)”View highlighted excerpt for this quote“20.8 (132)”View highlighted excerpt for this quote“13.2”View highlighted excerpt for this quote“16.4”View highlighted excerpt for this quote
Clinical response“30.9 (98)”View highlighted excerpt for this quote“59.6 (190)”View highlighted excerpt for this quote“62.1 (395)”View highlighted excerpt for this quote“28.6”View highlighted excerpt for this quote“31.2”View highlighted excerpt for this quote
Endoscopic improvement“7.9 (25)”View highlighted excerpt for this quote“29.8 (95)”View highlighted excerpt for this quote“34.4 (219)”View highlighted excerpt for this quote“21.9”View highlighted excerpt for this quote“26.6”View highlighted excerpt for this quote
HEMI“5.4 (17)”View highlighted excerpt for this quote“18.5 (59)”View highlighted excerpt for this quote“23.4 (149)”View highlighted excerpt for this quote“13.2”View highlighted excerpt for this quote“18.2”View highlighted excerpt for this quote
Symptomatic remission“19.9 (63)”View highlighted excerpt for this quote“37.9 (121)”View highlighted excerpt for this quote“40.7 (259)”View highlighted excerpt for this quote“18.1”View highlighted excerpt for this quote“21.0”View highlighted excerpt for this quote
Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Endpoint at Week 8, % (n)AT-IR-Yes placebo (N=69)AT-IR-Yes 25 mg (N=70)AT-IR-Yes 50 mg (N=149)AT-IR-No placebo (N=89)AT-IR-No 25 mg (N=90)AT-IR-No 50 mg (N=169)
Clinical remission“1.4 (1)”View highlighted excerpt for this quote“8.6 (6)”View highlighted excerpt for this quote“14.1 (21)”View highlighted excerpt for this quote“3.4 (3)”View highlighted excerpt for this quote“35.6 (32)”View highlighted excerpt for this quote“28.4 (48)”View highlighted excerpt for this quote
Endoscopic improvement“4.3 (3)”View highlighted excerpt for this quote“14.3 (10)”View highlighted excerpt for this quote“22.1 (33)”View highlighted excerpt for this quote“6.7 (6)”View highlighted excerpt for this quote“55.6 (50)”View highlighted excerpt for this quote“43.2 (73)”View highlighted excerpt for this quote
Symptomatic remission“10.1 (7)”View highlighted excerpt for this quote“27.1 (19)”View highlighted excerpt for this quote“34.9 (52)”View highlighted excerpt for this quote“23.6 (21)”View highlighted excerpt for this quote“54.4 (49)”View highlighted excerpt for this quote“46.7 (79)”View highlighted excerpt for this quote
HEMI“1.4 (1)”View highlighted excerpt for this quote“5.7 (4)”View highlighted excerpt for this quote“12.8 (19)”View highlighted excerpt for this quote“4.5 (4)”View highlighted excerpt for this quote“37.8 (34)”View highlighted excerpt for this quote“32.0 (54)”View highlighted excerpt for this quote
Clinical response“21.7 (15)”View highlighted excerpt for this quote“52.9 (37)”View highlighted excerpt for this quote“54.4 (81)”View highlighted excerpt for this quote“33.7 (30)”View highlighted excerpt for this quote“75.6 (68)”View highlighted excerpt for this quote“66.9 (113)”View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Endpoint at Week 8, % (n)AT-IR-Yes placebo (N=148)AT-IR-Yes 25 mg (N=146)AT-IR-Yes 50 mg (N=308)AT-IR-No placebo (N=169)AT-IR-No 25 mg (N=173)AT-IR-No 50 mg (N=328)
Clinical remission“3.4 (5)”View highlighted excerpt for this quote“6.8 (10)”View highlighted excerpt for this quote“13.3 (41)”View highlighted excerpt for this quote“5.3 (9)”View highlighted excerpt for this quote“26.6 (46)”View highlighted excerpt for this quote“27.7 (91)”View highlighted excerpt for this quote
Endoscopic improvement“6.8 (10)”View highlighted excerpt for this quote“13.0 (19)”View highlighted excerpt for this quote“24.4 (75)”View highlighted excerpt for this quote“8.9 (15)”View highlighted excerpt for this quote“43.9 (76)”View highlighted excerpt for this quote“43.9 (144)”View highlighted excerpt for this quote
Symptomatic remission“12.8 (19)”View highlighted excerpt for this quote“26.7 (39)”View highlighted excerpt for this quote“36.0 (111)”View highlighted excerpt for this quote“26.0 (44)”View highlighted excerpt for this quote“47.4 (82)”View highlighted excerpt for this quote“45.1 (148)”View highlighted excerpt for this quote
HEMI“4.1 (6)”View highlighted excerpt for this quote“6.8 (10)”View highlighted excerpt for this quote“14.9 (46)”View highlighted excerpt for this quote“6.5 (11)”View highlighted excerpt for this quote“28.3 (49)”View highlighted excerpt for this quote“31.4 (103)”View highlighted excerpt for this quote
Clinical response“20.9 (31)”View highlighted excerpt for this quote“46.6 (68)”View highlighted excerpt for this quote“55.8 (172)”View highlighted excerpt for this quote“39.6 (67)”View highlighted excerpt for this quote“70.5 (122)”View highlighted excerpt for this quote“68.0 (223)”View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: clinical response by prior JAK inhibitor failure and number of failed advanced therapies (nominal p-values)
Subset of AT-IR participantsPlacebo, % (n/N)Obefazimod 25 mg, % (n/N)25 mg minus placebo, % and p-valueObefazimod 50 mg, % (n/N)50 mg minus placebo, % and p-value
Prior JAK inhibitor failure“20.0 (7/35)”View highlighted excerpt for this quote“47.1 (16/34)”View highlighted excerpt for this quote“27.0 p = 0.0196”View highlighted excerpt for this quote“54.5 (30/55)”View highlighted excerpt for this quote“34.4 p = 0.0017”View highlighted excerpt for this quote
1 advanced therapy failure“24.2 (15/62)”View highlighted excerpt for this quote“53.3 (24/45)”View highlighted excerpt for this quote“30.5 p = 0.0018”View highlighted excerpt for this quote“50.7 (76/150)”View highlighted excerpt for this quote“25.3 p = 0.0008”View highlighted excerpt for this quote
2 advanced therapy failures“20.6 (7/34)”View highlighted excerpt for this quote“48.9 (22/45)”View highlighted excerpt for this quote“28.6 p = 0.0114”View highlighted excerpt for this quote“67.2 (43/64)”View highlighted excerpt for this quote“45.5 p < 0.0001”View highlighted excerpt for this quote
3 advanced therapy failures“14.3 (4/28)”View highlighted excerpt for this quote“42.4 (14/33)”View highlighted excerpt for this quote“27.3 p = 0.0297”View highlighted excerpt for this quote“61.5 (32/52)”View highlighted excerpt for this quote“46.3 p < 0.0001”View highlighted excerpt for this quote
4 or more advanced therapy failures“20.8 (5/24)”View highlighted excerpt for this quote“34.8 (8/23)”View highlighted excerpt for this quote“14.4 p = 0.2968”View highlighted excerpt for this quote“50.0 (21/42)”View highlighted excerpt for this quote“28.7 p = 0.0242”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Pooled ABTECT-1 and ABTECT-2: disease-specific and overall quality of life (IBDQ and EQ-5D-5L)

“The IBDQ has four domains, scores range 32-224; higher scores=better QoL. Meaningful within patient change (MWPC) for IBDQ total score was defined as ≥ 16 point change and remission as ≥ 170 points.” (opens the source at this quote in a new tab)

“All p-values are nominal.” (opens the source at this quote in a new tab)

“1272 pts were randomized and treated in ABTECT-1 (n = 636) and ABTECT-2 (n = 636); 1207 had IBDQ, 1137 had EQ-5D-5L Index and 1,180 had EQ-5D-5L VAS data at baseline.” (opens the source at this quote in a new tab)

“At baseline, pts had mean IBDQ total scores of 110.8, 110.8, and 109.7 for Obe-50, Obe-25, and PBO, respectively. At Week 8, Obe-treated pts reported higher mean IBDQ scores vs PBO: 161.9, 159.2, and 135.7 in the Obe-50, Obe-25 and PBO groups respectively (Obe-50:Δ25.97 and Obe-25:Δ22.33, p < 0.0001).” (opens the source at this quote in a new tab)

“At Week 8, a greater proportion of Obe-treated pts had a MWPC: 60.9% for Obe-50 and 56.9% for Obe-25 vs 39.8% for PBO (Obe-50:Δ21.20 and Obe-25:Δ17.07, p < 0.0001). More Obe-treated pts without IBDQ remission at baseline achieved IBDQ remission: 36.7% for Obe-50 and 33.2% for Obe-25 vs 19.6% for PBO (Obe-50:Δ17.13 and Obe-25:Δ13.56, p < 0.001).” (opens the source at this quote in a new tab)

“At baseline, mean EQ-5D-5L Index scores were 0.66, 0.64, and 0.63 for Obe-50, Obe-25, and PBO, respectively. At Week 8, Obe-treated pts reported higher EQ-5D-5L Index scores vs PBO: mean 0.82, 0.81, and 0.71 in the Obe-50, Obe-25 and PBO groups, respectively (Obe-50:Δ0.10 and Obe-25:Δ0.09, p < 0.0001).” (opens the source at this quote in a new tab)

“At Week 8, a greater proportion of Obe-treated pts had a MWPC on the EQ-5D-5L Index: 41.0% for Obe-50 and 38.9% for Obe-25 vs 28.5% for PBO (Obe-50:Δ12.59 and Obe-25:Δ10.36, p < 0.01).” (opens the source at this quote in a new tab)

Safety results
Treatment-emergent adverse events at Week 8 reported by the company
Event, n (%)Placebo (N=158)Obefazimod 25 mg (N=160)Obefazimod 50 mg (N=318)
Any TEAE“84 (53.2%)”“75 (46.9%)”“189 (59.4%)”
TEAE leading to study drug discontinuation“6 (3.8%)”“0 (0.0%)”“17 (5.3%)”
Serious TEAE“3 (1.9%)”“1 (0.6%)”“14 (4.4%)”
Malignancy“0 (0.0%)”“0 (0.0%)”“1 (0.3%)”
Serious or severe (grade 3 or higher) infections and opportunistic infections“1 (0.6%)”“1 (0.6%)”“2 (0.6%)”
Non-serious adverse events at a 5% reporting threshold in the posted results
Pooled ABTECT-1 and ABTECT-2: adverse events leading to study drug discontinuation
Event, n (%)Obefazimod 50 mg (n=636)Obefazimod 25 mg (n=319)Placebo (n=317)
Ulcerative colitis“7 (1.1)”“2 (0.6)”“7 (2.2)”
Headache“7 (1.1)”“1 (0.3)”“0”
Vomiting“4 (0.6)”“1 (0.3)”“0”
Nausea“3 (0.5)”“1 (0.3)”“0”
Pancreatitis acute“2 (0.3)”“1 (0.3)”“1 (0.3)”
Study limitations
Summary: study limitations
  • Duration and comparator: ABTECT-1 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks. It has no active comparator, and the durability of response is assessed only in the separate ABTECT Maintenance trial, which enrolled Week 8 responders from both induction trials.
  • Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), congress abstracts and posters, and company press releases and filings. The counts differ between sources: the registry lists 639 participants enrolled, the participant flow starts with 318, 161, and 160 by arm, and the Full Analysis Set holds 636, because one participant randomized to 25 mg and two randomized to placebo were never dosed.
  • Placebo group and background therapy: randomization was 2:1:1, so the placebo arm holds 158 participants, of whom 4 (2.5%) reached clinical remission at Week 8. Stable oral 5-ASA and oral corticosteroids were allowed, and the protocol states that such background therapy “may be partially effective at controlling UC symptoms”.
  • Population: participants were 16 years or older (18 or older in the EU, the EEA, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Isolated proctitis, primary sclerosing cholangitis, creatinine clearance below 60 mL/min, QT prolongation, and HIV infection were exclusions. Of the 636 participants analyzed, 288 (45.3%) had a prior inadequate response to an advanced therapy and 52 had a prior inadequate response to a JAK inhibitor; 48 were 65 years or older, 10 were Black or African American, and 166 were Asian. The registry lists 264 locations.
  • Endpoints for two regulators: the FDA primary endpoint is clinical remission by the modified Mayo Score; for the EMA, endoscopic improvement and symptomatic remission are co-primary endpoints, and symptomatic remission was not multiplicity controlled under the FDA testing scheme. The Form 20-F describes the primary endpoint as requiring a stool frequency subscore “not greater than baseline”, a condition the registry and protocol definitions do not state.
  • Statistical reporting: the posted protocol omits the assumed treatment difference, power, and placebo remission rate behind the sample size of 612 (“difference of at least” is followed by no value). The pooled ABTECT-1 and ABTECT-2 analyses, including the pooled subgroup analyses, report nominal p-values, and the analysis by disease extent is post hoc. Subgroups are small: among participants with prior advanced therapy inadequate response, 6 of 70 (8.6%) receiving 25 mg and 1 of 69 (1.4%) receiving placebo reached clinical remission (p=0.0556).
  • Safety reporting: serious adverse events occurred in 14 of 318 participants (4.40%) receiving 50 mg, 1 of 160 (0.63%) receiving 25 mg, and 3 of 158 (1.90%) receiving placebo; events in the 50 mg arm included one myocardial infarction, one acute pancreatitis, one pancreatitis, and one stage I prostate cancer. Figures differ between company sources: the rate of discontinuation for headache is given as “0%–1.6%” in the UEG Week 2025 abstract and “0-1.1%” in the integrated safety abstract, and pooled headache with 50 mg as 24.1% in a press release and 23.3% (148 of 636) in the integrated safety poster.

ABTECT-2

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by arm in the posted results
PopulationABX464 50 mgABX464 25 mgPlaceboTotal
Started“318”“159”“159”Not reported
Baseline“318”“159”“159”“636”
Adverse events (at risk)“0/318 (0.00%)”“0/159 (0.00%)”“0/159 (0.00%)”Not reported
Description of analysis sets
Results
Participant disposition
Participant flow by arm in the posted results
DispositionABX464 50 mgABX464 25 mgPlacebo
Started“318”“159”“159”
Completed“291”“142”“145”
Not completed“27”“17”“14”
Adverse event“13”“8”“8”
Lack of efficacy“2”“2”“1”
Lost to follow-up“3”“0”“0”
Protocol violation“0”“1”“2”
Withdrawal by subject“9”“6”“3”
Baseline characteristics
Baseline characteristics by arm in the posted results
CharacteristicABX464 50 mg (n=318)ABX464 25 mg (n=159)Placebo (n=159)Total (n=636)
Age, years, mean (SD)“41.4(13.64)”“41.3(12.83)”“41.6(14.68)”“41.4(13.69)”
Age 65 years or older, participants“19”“6”“16”“41”
Female, participants“138”“60”“58”“256”
Male, participants“180”“99”“101”“380”
Asian, participants“66”“29”“39”“134”
Black or African American, participants“6”“3”“4”“13”
White, participants“231”“116”“108”“455”
Weight, kg, mean (SD)“71.75(17.101)”“73.37(16.050)”“73.91(17.387)”“72.69(16.919)”
Duration of ulcerative colitis, years, mean (SD)“7.74(7.193)”“7.92(6.769)”“7.75(6.503)”“7.79(6.911)”
At least one prior advanced therapy inadequate response, participants“159”“76”“79”“314”
Inadequate response to JAK inhibitors among those with AT-IR, participants“33”“19”“20”“72”
Modified Mayo Score, mean (SD)“6.9(1.11)”“7.0(1.04)”“6.8(0.98)”“6.9(1.06)”
Mayo endoscopic subscore 2, participants“130”“56”“64”“250”
Mayo endoscopic subscore 3, participants“188”“103”“95”“386”
Fecal calprotectin, µg/g, mean (SD)“3759.05(7548.48)”“4121.86(7081.92)”“4499.81(8074.99)”“4038.06(7569.95)”
Efficacy results
Primary and key secondary endpoints at Week 8
Endpoint at Week 8, % (n)Placebo (N=159)Obefazimod 25 mg (N=159)Obefazimod 50 mg (N=318)25 mg minus placebo, %25 mg p-value50 mg minus placebo, %50 mg p-value
Clinical remission (primary)“6.3 (10)”View highlighted excerpt for this quote“11.3 (18)”View highlighted excerpt for this quote“19.8 (63)”View highlighted excerpt for this quote“5.1”View highlighted excerpt for this quote“p = 0.1034”View highlighted excerpt for this quote“13.4”View highlighted excerpt for this quote“p = 0.0001”View highlighted excerpt for this quote
Clinical response“33.3 (53)”View highlighted excerpt for this quote“53.5 (85)”View highlighted excerpt for this quote“63.2 (201)”View highlighted excerpt for this quote“20.1”View highlighted excerpt for this quote“p = 0.0002”View highlighted excerpt for this quote“29.6”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Endoscopic improvement“10.1 (16)”View highlighted excerpt for this quote“22.0 (35)”View highlighted excerpt for this quote“35.5 (113)”View highlighted excerpt for this quote“12.0”View highlighted excerpt for this quote“p = 0.0029”View highlighted excerpt for this quote“25.4”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
HEMI“7.5 (12)”View highlighted excerpt for this quote“13.2 (21)”View highlighted excerpt for this quote“23.9 (76)”View highlighted excerpt for this quote“5.7”View highlighted excerpt for this quote“p = 0.0932”View highlighted excerpt for this quote“16.4”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Symptomatic remission“22.0 (35)”View highlighted excerpt for this quote“33.3 (53)”View highlighted excerpt for this quote“40.3 (128)”View highlighted excerpt for this quote“11.4”View highlighted excerpt for this quote“p = 0.0227”View highlighted excerpt for this quote“18.0”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Participants meeting each endpoint at Week 8 in the posted results
Endpoint at Week 8, participantsABX464 50 mg (n=318)ABX464 25 mg (n=159)Placebo (n=159)
Clinical remission per modified Mayo Score (primary)“63”“18”“10”
Endoscopic improvement“113”“35”“16”
Clinical response per modified Mayo Score“201”“85”“53”
HEMI per Geboes“76”“21”“12”
Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Endpoint at Week 8, % (n)AT-IR-Yes placebo (N=79)AT-IR-Yes 25 mg (N=76)AT-IR-Yes 50 mg (N=159)AT-IR-No placebo (N=80)AT-IR-No 25 mg (N=83)AT-IR-No 50 mg (N=159)
Clinical remission“5.1 (4)”View highlighted excerpt for this quote“5.3 (4)”View highlighted excerpt for this quote“12.6 (20)”View highlighted excerpt for this quote“7.5 (6)”View highlighted excerpt for this quote“16.9 (14)”View highlighted excerpt for this quote“27.0 (43)”View highlighted excerpt for this quote
Endoscopic improvement“8.9 (7)”View highlighted excerpt for this quote“11.8 (9)”View highlighted excerpt for this quote“26.4 (42)”View highlighted excerpt for this quote“11.3 (9)”View highlighted excerpt for this quote“31.3 (26)”View highlighted excerpt for this quote“44.7 (71)”View highlighted excerpt for this quote
Symptomatic remission“15.2 (12)”View highlighted excerpt for this quote“26.3 (20)”View highlighted excerpt for this quote“37.1 (59)”View highlighted excerpt for this quote“28.8 (23)”View highlighted excerpt for this quote“39.8 (33)”View highlighted excerpt for this quote“43.4 (69)”View highlighted excerpt for this quote
HEMI“6.3 (5)”View highlighted excerpt for this quote“7.9 (6)”View highlighted excerpt for this quote“17.0 (27)”View highlighted excerpt for this quote“8.8 (7)”View highlighted excerpt for this quote“18.1 (15)”View highlighted excerpt for this quote“30.8 (49)”View highlighted excerpt for this quote
Clinical response“20.3 (16)”View highlighted excerpt for this quote“40.8 (31)”View highlighted excerpt for this quote“57.2 (91)”View highlighted excerpt for this quote“46.3 (37)”View highlighted excerpt for this quote“65.1 (54)”View highlighted excerpt for this quote“69.2 (110)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events at Week 8 reported by the company
Event, n (%)Placebo (N=159)Obefazimod 25 mg (N=159)Obefazimod 50 mg (N=318)
Any TEAE“77 (48.4%)”“81 (50.9%)”“194 (61.0%)”
TEAE leading to study drug discontinuation“9 (5.7%)”“8 (5.0%)”“15 (4.7%)”
Serious TEAE“7 (4.4%)”“6 (3.8%)”“6 (1.9%)”
Malignancy“0 (0.0%)”“0 (0.0%)”“0 (0.0%)”
Serious or severe (grade 3 or higher) infections and opportunistic infections“0 (0.0%)”“0 (0.0%)”“2 (0.6%)”
Non-serious adverse events at a 5% reporting threshold in the posted results
Study limitations
Summary: study limitations
  • Duration and comparator: ABTECT-2 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks, and has no active comparator. Durability is assessed only in the separate ABTECT Maintenance trial. The pooled ABTECT-1 and ABTECT-2 analyses, including all patient-reported outcome results, are recorded under ABTECT-1; no patient-reported outcome result specific to ABTECT-2 was identified.
  • Primary endpoint by dose: the 50 mg dose met the primary endpoint (clinical remission 19.8% against 6.3% with placebo; difference 13.4%, p=0.0001). The 25 mg dose did not (11.3% against 6.3%; difference 5.1%, p=0.1034), so under the hierarchical testing scheme the p-values for its key secondary endpoints are nominal. The company states that a “slightly more severe and refractory population” was randomized to 25 mg in ABTECT-2 than in ABTECT-1; in the posted baseline data, 76 of 159 participants receiving 25 mg had a prior advanced therapy inadequate response and 103 had a Mayo endoscopic subscore of 3.
  • Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), a congress abstract, and company press releases and filings. The posted results do not specify the analysis population for baseline characteristics or outcome measures.
  • Population: participants were 16 years or older (18 or older in the EU, the EEA, Israel, Serbia, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Of 636 participants, 314 (49.4%) had a prior advanced therapy inadequate response and 72 had a prior inadequate response to a JAK inhibitor; 41 were 65 years or older and 13 were Black or African American. Randomization was also stratified by region (Japan or rest of world), and the registry lists 262 locations. The protocol excludes the region factor from the primary analysis model “for consistency with ABX464-105”.
  • Background therapy: stable oral 5-ASA and oral corticosteroids were allowed in all arms, and the protocol states that such therapy “may be partially effective at controlling UC symptoms”.
  • Subgroups: subgroup results by prior advanced therapy inadequate response come from small groups. Among participants with a prior inadequate response, clinical remission occurred in 4 of 76 (5.3%) receiving 25 mg and 4 of 79 (5.1%) receiving placebo (p=0.8529), and in 20 of 159 (12.6%) receiving 50 mg (p=0.0652).
  • Safety reporting: serious adverse events occurred in 6 of 318 participants (1.89%) receiving 50 mg, 6 of 159 (3.77%) receiving 25 mg, and 7 of 159 (4.40%) receiving placebo. Non-serious lipase increase was reported in 19 of 318 (5.97%) receiving 50 mg and 4 of 159 (2.52%) receiving placebo, and serious acute pancreatitis in 1 participant receiving 25 mg and 1 receiving placebo.

ABTECT maintenance

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Part 1 analysis population: 580 obefazimod induction responders
GroupParticipants
Obefazimod induction responders“Obefazimod Induction Responders (n=580)”
Placebo“Placebo (n=192)”
Obefazimod 25 mg“25 mg (n=193)”
Obefazimod 50 mg“50 mg (n=195)”
Part 2 induction non-responders and Part 1 relapsers analyzed for efficacy
GroupParticipants
Induction non-responders, obefazimod 25 mg“(N=81)”
Induction non-responders, obefazimod 50 mg“(N=148)”
Part 1 relapsers, placebo then obefazimod 50 mg“(N=109)”
Part 1 relapsers, obefazimod 25 mg then 50 mg“(N=33)”
Description of analysis sets
Results
Participant disposition
Week 44 completion without relapse or treatment switch, by group
MeasurePlaceboObefazimod 25 mgObefazimod 50 mg
Study participants“192”“193”“195”
Week 44 completion rate“66 (34.3%)”“152 (78.8%)”“160 (82.1%)”
Baseline characteristics
Part 1 baseline characteristics by group
CharacteristicPlaceboObefazimod 25 mgObefazimod 50 mg
Study participants“192”“193”“195”
Age (years), mean (SD)“41.3 (13.4)”“43.0 (13.7)”“42.3 (14.4)”
Induction baseline modified Mayo Score, mean (SD)“6.9 (1.1)”“6.7 (1.1)”“6.9 (1.2)”
Duration of disease (years), mean (SD)“8.1 (7.6)”“8.1 (7.4)”“7.8 (6.9)”
Induction baseline fecal calprotectin (mg/g), median“1,202”“1,585”“1,568”
Corticosteroid use at maintenance baseline“35.9%”“41.5%”“40.5%”
Clinical remission at maintenance baseline“27.1%”“37.8%”“32.3%”
Prior advanced therapy failure“37.5%”“39.4%”“46.2%”
Efficacy results
Part 1 primary and key secondary endpoints at Week 44
Endpoint at Week 44Placebo (N=192)Obefazimod 25 mg (N=193)Obefazimod 50 mg (N=195)Difference, 25 mgDifference, 50 mgP value (both doses)
Clinical remission, n (%)“20 (10.4%)”“98 (50.8%)”“100 (51.3%)”“∆39.3%”“∆40.3%”“<0.0001”
Endoscopic improvement, n (%)“24 (12.5%)”“106 (54.9%)”“125 (64.1%)”“∆42.5%”“∆51.0%”“<0.0001”
Endoscopic remission, n (%)“19 (9.9%)”“80 (41.5%)”“93 (47.7%)”“∆31.4%”“∆37.8%”“<0.0001”
HEMI, n (%)“20 (10.4%)”“97 (50.3%)”“112 (57.4%)”“∆39.4%”“∆46.5%”“<0.0001”
Corticosteroid-free clinical remission, n (%)“19 (9.9%)”“87 (45.1%)”“93 (47.7%)”“∆35.1%”“∆38.0%”“<0.0001”
Sustained clinical remission, n/N (%)“8/51 (15.7%)”“49/73 (67.1%)”“40/61 (65.6%)”“∆52.8%”“∆49.1%”“<0.0001”
Clinical endpoints at Week 52 by prior inadequate response to advanced therapy
Subgroup and endpointPlacebo, n/NObefazimod 25 mg, n/NObefazimod 50 mg, n/NDifference, 25 mgP value, 25 mgDifference, 50 mgP value, 50 mg
No prior AT-IR: clinical remission“15/120”“72/117”“62/105”“∆ 48%”“p<0.0001”“∆ 45%”“p<0.0001”
No prior AT-IR: corticosteroid-free clinical remission“15/120”“64/117”“59/105”“∆ 42%”“p<0.0001”“∆ 43%”“p<0.0001”
No prior AT-IR: sustained clinical remission“5/38”“42/58”“27/38”“∆ 62%”“p<0.0001”“∆ 55%”“p=0.0003”
Prior AT-IR: clinical remission“5/72”“26/76”“38/90”“∆ 28%”“p<0.0001”“∆ 33%”“p<0.0001”
Prior AT-IR: corticosteroid-free clinical remission“4/72”“23/76”“34/90”“∆ 26%”“p=0.0001”“∆ 31%”“p<0.0001”
Prior AT-IR: sustained clinical remission“3/13”“7/15”“13/23”“∆ 24%”“p=0.6873”“∆ 30%”“p=0.0915”
Endoscopic and histologic-endoscopic endpoints at Week 52 by prior inadequate response to advanced therapy
Subgroup and endpointPlacebo, n/NObefazimod 25 mg, n/NObefazimod 50 mg, n/N
No prior AT-IR: endoscopic improvement“18/120”“77/117”“77/105”
No prior AT-IR: endoscopic remission“15/120”“62/117”“58/105”
No prior AT-IR: HEMI“15/120”“71/117”“68/105”
Prior AT-IR: endoscopic improvement“6/72”“29/76”“48/90”
Prior AT-IR: endoscopic remission“4/72”“18/76”“35/90”
Prior AT-IR: HEMI“5/72”“26/76”“44/90”
Clinical remission at Week 52 by number of prior advanced therapies with inadequate response and after JAK inhibitor failure
SubgroupPlacebo, n/NObefazimod 25 mg, n/NObefazimod 50 mg, n/NDifference, 25 mgP value, 25 mgDifference, 50 mgP value, 50 mg
No prior AT-IR“15/120”“72/117”“62/105”“∆ 49%”“p<0.0001”“∆ 47%”“p<0.0001”
One prior AT-IR“4/27”“12/31”“17/41”“∆ 24%”“p=0.2785”“∆ 27%”“p=0.0584”
Two prior AT-IR“0/24”“7/22”“8/19”“∆ 32%”“p=0.0215”“∆ 42%”“p=0.0014”
Three prior AT-IR“1/12”“4/12”“10/21”“∆ 25%”“p=0.0771”“∆ 39%”“p=0.0968”
Four or more prior AT-IR“0/9”“3/11”“3/9”“∆ 27%”“NC”“∆ 33%”“p=0.1967”
Prior JAK inhibitor inadequate response“0/16”“4/14”“5/15”“∆ 29%”“p=0.0190”“∆ 33%”“p=0.0375”
Part 2: induction non-responders continuing obefazimod, exploratory endpoints at Week 44
EndpointObefazimod 25 mg (N=81)Obefazimod 50 mg (N=148)
Clinical remission“23.5%”“37.2%”
Clinical response“50.6%”“61.5%”
Endoscopic improvement“28.4%”“48.0%”
HEMI“23.5%”“44.6%”
Endoscopic remission“22.2%”“34.5%”
Part 2: Part 1 relapsers re-treated with obefazimod 50 mg, exploratory endpoints at Week 44
EndpointPlacebo in Part 1, then 50 mg (N=109)Obefazimod 25 mg in Part 1, then 50 mg (N=33)
Clinical remission“45.0%”“45.5%”
Clinical response“69.7%”“66.7%”
Endoscopic improvement“54.1%”“45.5%”
HEMI“47.7%”“39.4%”
Endoscopic remission“32.1%”“24.2%”
Health-related quality of life and patient-reported outcomes
Safety results
Part 1 treatment-emergent adverse events over 44 weeks
Event, n (%)Placebo (N=192)Obefazimod 25 mg (N=193)Obefazimod 50 mg (N=195)
Any TEAE“96 (50.0%)”“112 (58.0%)”“140 (71.8%)”
TEAE leading to study drug discontinuation“13 (6.8%)”“5 (2.6%)”“9 (4.6%)”
Serious TEAE“8 (4.2%)”“5 (2.6%)”“11 (5.6%)”
Death“0”“0”“0”
Serious or severe (grade 3 or higher) infections and opportunistic infections“2 (1.0%)”“2 (1.0%)”“1 (0.5%)”
Acute pancreatitis“0”“0”“0”
Cardiac abnormalities suggestive of cardiac fibrosis“0”“0”“0”
Malignancy other than NMSC: prostate cancer“0”“0”“1 (0.5%)”
Malignancy other than NMSC: breast cancer“0”“0”“1 (0.5%)”
Malignancy other than NMSC: colonic dysplasia“0”“0”“1 (0.5%)”
NMSC: basal cell carcinoma“1 (0.5%)”“0”“2 (1.1%)”
NMSC: squamous cell carcinoma“0”“1 (0.5%)”“2 (1.1%)”
Part 2 treatment-emergent adverse events in induction non-responders and Part 1 relapsers
Event, n (%)Obefazimod 25 mg (N=186)Obefazimod 50 mg (N=447)
Any TEAE“132 (71.0%)”“307 (68.7%)”
TEAE leading to study drug discontinuation“21 (11.3%)”“27 (6.0%)”
Serious TEAE“16 (8.6%)”“23 (5.1%)”
Death, not treatment related“1 (0.5%)”“0”
Pregnancy“1 (0.5%)”“1 (0.2%)”
Serious or severe (grade 3 or higher) infections and opportunistic infections“5 (2.7%)”“5 (1.1%)”
Malignancies excluding NMSC“0”“2 (0.4%)”
NMSC“2 (1.1%)”“2 (0.4%)”
Acute pancreatitis“1 (0.5%)”“1 (0.2%)”
Cardiac abnormalities suggestive of cardiac fibrosis“0”“0”
Exposure-adjusted incidence of malignancies excluding NMSC (post-hoc), with the company's expected background range
Analysis setPlacebo, IR/100 PY25 mg, IR/100 PY50 mg, IR/100 PYAll active, IR/100 PYExpected UC background
Integrated UC program (phase 2 and phase 3)“0.00”“0.00”“0.64”“0.35”“0.30 – 0.70”
Phase 3 maintenance (Part 1 and Part 2)“0.00”“0.00”“0.91”“0.56”“0.30 – 0.70”
Part 2 only“-”“0.00”“0.69”“0.48”“0.30 – 0.70”
Exposure-adjusted incidence of non-melanoma skin cancer (post-hoc), with the company's expected background range
Analysis setPlacebo, IR/100 PY25 mg, IR/100 PY50 mg, IR/100 PYAll active, IR/100 PYExpected UC background
Integrated UC program (phase 2 and phase 3)“0.46”“0.53”“0.64”“0.59”“0.70 – 1.40”
Phase 3 maintenance (Part 1 and Part 2)“0.68”“1.09”“1.37”“1.26”“0.70 – 1.40”
Part 2 only“-”“1.52”“0.69”“0.95”“0.70 – 1.40”
Acute pancreatitis and cardiac abnormalities suggestive of cardiac fibrosis: ABTECT maintenance Part 1
EventPlacebo (N=192)Obefazimod 25 mg (N=193)Obefazimod 50 mg (N=195)
Acute pancreatitis“0”“0”“0”
Cardiac abnormalities suggestive of cardiac fibrosis“0”“0”“0”
Study limitations
Summary

As of November 2026, the results of ABTECT Maintenance come only from company press releases of June 1 and June 29, 2026, a prospectus supplement, and two slide presentations at UEG Week 2026. No peer-reviewed publication exists, the ClinicalTrials.gov record shows “No Results Posted”, and the EU register states that the trial has not ended; no protocol or statistical analysis plan for this trial is posted on ClinicalTrials.gov. The long-term extension continues to an estimated study completion in May 2030.

Part 1 is a randomized withdrawal design. Its 580 analyzed participants (192 placebo, 193 obefazimod 25 mg, 195 obefazimod 50 mg) had all responded to 8 weeks of obefazimod induction, so the placebo group measures withdrawal of obefazimod after an initial response; participants without an induction response are reported separately in Part 2. Of the 678 induction responders who entered Part 1, placebo induction responders were kept on blinded placebo and are outside the 580-participant comparison. Completion of Week 44 without relapse or treatment switch was 66 of 192 (34.3%) with placebo, against 152 of 193 (78.8%) and 160 of 195 (82.1%) with obefazimod 25 mg and 50 mg, so most placebo participants left the randomized treatment before Week 44; the handling of these participants in the efficacy analysis has not been published.

The timepoint is reported as Week 44 in the press releases and registry and as “Week 52” in the UEG Week slides, which count the 8-week induction. The registries differ: ClinicalTrials.gov names clinical remission at Week 44 as the Part 1 primary endpoint, while the EU register states the Part 1 objective as comparing obefazimod with placebo on “endoscopic improvement and symptomatic remission” and lists clinical remission at Week 44 among the Part 1 endpoints. Symptomatic remission (66.8% and 65.6% with obefazimod against 22.9% with placebo) is reported only in the slides, and its printed definition reads “RBS=0, SFS <1”. Corticosteroid-free clinical remission is registered in the subpopulation receiving corticosteroids at maintenance entry, while the reported counts (19 of 192, 87 of 193, and 93 of 195) use all randomized participants as the denominator.

Prior advanced therapy failure was more frequent in the 50 mg group (46.2%) than in the 25 mg (39.4%) and placebo (37.5%) groups. Placebo-adjusted differences were numerically smaller in participants with prior inadequate response to advanced therapy (clinical remission differences of 28% and 33%) than in those without (48% and 45%). The subgroup analyses by number of prior advanced therapies and after JAK inhibitor failure involved 9 to 41 participants per group, and their differences are unadjusted with nominal p-values that the presenters describe as “descriptive rather than confirmatory”; the sustained clinical remission subgroup with prior advanced therapy failure included 13, 15, and 23 participants.

Part 2 efficacy results come from groups without a placebo comparator: induction non-responders who continued obefazimod (81 on 25 mg and 148 on 50 mg) and Part 1 relapsers re-treated with open-label 50 mg (109 previously on placebo and 33 previously on 25 mg). The company labels these results exploratory and the integrated safety analyses post-hoc.

Malignancy findings rest on small numbers of events. In Part 1, the 50 mg group had one prostate cancer, one breast cancer, and one colonic dysplasia, listed by the release under malignancies other than NMSC, and four NMSC (two basal cell and two squamous cell carcinomas), against one NMSC with placebo and one with 25 mg; no malignancy other than NMSC occurred with placebo or 25 mg. Part 2 added two malignancies excluding NMSC (a myeloproliferative neoplasm and a prostate cancer, both in Part 1 placebo relapsers re-treated with 50 mg) and four NMSC, two of which the investigators judged probably related to study drug. In the phase 3 maintenance dataset, the exposure-adjusted incidence of NMSC was 1.37 per 100 patient-years with 50 mg and 0.68 with placebo, and of malignancies excluding NMSC 0.91 with 50 mg and 0.00 with placebo. The company's comparison of these rates with a “UC background reference range” is post-hoc and compares the trial's rates with an external reference range from published studies. Part 2 also reported one death from suspected pulmonary embolism, assessed as unrelated, and one case of acute pancreatitis in each dose group, an event with no cases in Part 1.

ABX464-103

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Model description“Randomized, double blind, placebo controlled, parallel groups”
Masking“Quadruple”
Phase“Phase 2”
Enrollment (actual)“355”
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed for the primary outcome in the posted results
GroupParticipants analyzed, change in MMS at week 8
ABX464 100 mg“58”
ABX464 50 mg“54”
ABX464 25 mg“59”
Matching placebo“60”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MeasureABX464 100 mgABX464 50 mgABX464 25 mgMatching placebo
Started“64”“63”“63”“64”
Treated“64”“63”“62”“64”
Full analysis set“64”“63”“61”“64”
Completed“54”“53”“58”“57”
Not completed“10”“10”“5”“7”
Baseline characteristics
Baseline characteristics in the posted results
CharacteristicABX464 100 mgABX464 50 mgABX464 25 mgMatching placeboTotal
Participants“64”“63”“61”“64”“252”
Age, years, mean (SD)“42.2(12.34)”“40.2(13.94)”“41.5(14.16)”“41.1(14.43)”“41.2(13.67)”
Female“23”“36”“21”“24”“104”
Male“41”“27”“40”“40”“148”
Baseline MMS 5 to 6“17”“16”“17”“21”“71”
Baseline MMS 7 to 9“47”“47”“44”“42”“180”
Participants enrolled by country in the posted results, selected countries
CountryTotal participants
Poland“70”
Ukraine“32”
France“30”
Hungary“22”
Italy“20”
United States“2”
Efficacy results
Primary outcome in the posted results: least squares mean change in MMS at week 8
GroupLeast squares mean95% confidence interval
ABX464 100 mg“-2.9”“(-3.4 to -2.5)”
ABX464 50 mg“-3.2”“(-3.7 to -2.7)”
ABX464 25 mg“-3.1”“(-3.6 to -2.6)”
Matching placebo“-1.9”“(-2.4 to -1.5)”
Secondary outcomes at week 8 in the posted results: number of participants
Outcome (participants analyzed per group)ABX464 100 mgABX464 50 mgABX464 25 mgMatching placebo
Clinical remission per MMS (64, 63, 61, 64)“16”“11”“16”“8”
Clinical response (64, 63, 61, 64)“32”“37”“38”“22”
Endoscopic improvement (54, 53, 58, 59)“24”“21”“20”“8”
Endoscopic remission (54, 53, 58, 59)“2”“5”“4”“5”
Mucosal healing (64, 63, 61, 64)“0”“1”“0”“2”
Secondary outcomes at week 16 in the posted results: number of participants
Outcome (participants analyzed per group)ABX464 100 mgABX464 50 mgABX464 25 mgMatching placebo
Clinical remission per MMS (31, 30, 37, 46)“7”“6”“9”“6”
Clinical response (31, 30, 37, 46)“19”“20”“25”“20”
Endoscopic improvement (32, 31, 38, 46)“11”“12”“11”“9”
Endoscopic remission (32, 31, 38, 46)“1”“1”“2”“3”
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

ABX464-103 was a phase 2b, randomized, double-blind, placebo-controlled dose-ranging induction trial with 4 parallel groups; 254 participants were randomized and 252 were included in the full analysis set. The primary endpoint was the change from baseline in modified Mayo score at week 8, and the protocol also defined clinical remission, clinical response, and endoscopic improvement as outcomes. The posted results report the primary outcome for 58, 54, 59, and 60 participants in the 100 mg, 50 mg, 25 mg, and placebo groups, against full analysis set sizes of 64, 63, 61, and 64. The protocol scheduled week 16 endoscopy only for participants without endoscopic improvement at week 8, and the week 16 outcomes were analyzed in participants “with data available for baseline and the respective visit”. The protocol limited participants with previous exposure to biologics or JAK inhibitors to 60%, those with previous vedolizumab to 20%, and those with previous JAK inhibitors to 10%. Of 252 participants, 2 were enrolled in the United States, and race and ethnicity were not collected. The protocol planned IBDQ assessment at Week 8 and Week 16, and no IBDQ results were located in the PubMed abstract or the posted results. Headache was reported in 27 of 64, 19 of 63, 13 of 62, and 5 of 64 participants in the 100 mg, 50 mg, 25 mg, and placebo groups. The PubMed abstract gives NCT04023396, the record of the open-label maintenance study, as the trial registration.

ABX464-104

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“N/A”
Interventional model“Single Group Assignment”
Model description“open-label, follow-up study”
Masking“None (Open Label)”
Phase“Phase 2”
Enrollment (actual)“217”
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the posted results
MeasureQuoted record
Enrollment (actual)“217”
Overall number of baseline participants“217”
Overall number of participants analyzed, clinical remission at week 48“217”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MeasureParticipants
Started“217”
Completed“164”
Not completed“53”
Adverse event“16”
Death“1”
Lack of efficacy“3”
Lost to follow-up“1”
Other reason (e.g., Ukraine Crisis)“10”
Physician decision“4”
Pregnancy“4”
Withdrawal by subject“14”
Baseline characteristics
Demographic and baseline characteristics in the published report
CharacteristicTotal (N = 217)
Age, years, mean (SD)“42.1 (13.8)”View highlighted excerpt for this quote
Male, n (%)“133 (61.3)”View highlighted excerpt for this quote
Female, n (%)“84 (38.7)”View highlighted excerpt for this quote
Obefazimod 25 mg during induction, n (%)“58 (26.7)”View highlighted excerpt for this quote
Obefazimod 50 mg during induction, n (%)“51 (23.5)”View highlighted excerpt for this quote
Obefazimod 100 mg during induction, n (%)“53 (24.4)”View highlighted excerpt for this quote
Placebo during induction, n (%)“55 (25.3)”View highlighted excerpt for this quote
Naïve to biologics or JAK inhibitors, n (%)“119 (54.8)”View highlighted excerpt for this quote
Inadequate response to biologics or JAK inhibitors, n (%)“98 (45.2)”View highlighted excerpt for this quote
Inadequate response to 2 or more biologics or JAK inhibitors, n (%)“70 (71.4)”View highlighted excerpt for this quote
Concomitant corticosteroids, n (%)“120 (55.3)”View highlighted excerpt for this quote
Concomitant 5-ASA, n (%)“159 (73.3)”View highlighted excerpt for this quote
Fecal calprotectin, µg/g, mean (SD)“900.1 (1574.5)”View highlighted excerpt for this quote
Efficacy results
Primary outcome in the posted results: clinical remission at week 48 (of 217)
OutcomeParticipants
Clinical remission at week 48“119”
Secondary outcomes in the posted results: number of participants (of 217)
OutcomeWeek 48Week 96
Clinical response“177”“158”
Endoscopic improvement“133”“128”
Endoscopic remission“72”“78”
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events over 96 weeks
Adverse events in the posted results: participants affected / at risk (%)
EventABX464 50 mg
All-cause mortality“1/217 (0.46%)”
Serious adverse events, total“18/217 (8.29%)”
Other adverse events, total“148/217 (68.20%)”
COVID-19“31/217 (14.29%)”
Headache“25/217 (11.52%)”
Colitis ulcerative“17/217 (7.83%)”
Nasopharyngitis“15/217 (6.91%)”
Study limitations
Summary

ABX464-104 was a single-group, open-label study without a control group, in which all 217 participants received obefazimod 50 mg once daily regardless of their induction treatment or response; the investigators state that “the results must be interpreted with caution due to the absence of a control group”. Entry into the second year required clinical response at week 48, and 6 participants did not continue because they did not achieve it or were unwilling. Efficacy was analyzed with nonresponder imputation, and the statistical analysis plan carried forward week 48 results for completers missing a week 96 assessment. Corticosteroid tapering was recommended and not mandatory; the protocol defined glucocorticoid-free clinical remission as no glucocorticoids for at least 8 weeks before week 48, and the published analysis used cessation for at least 12 weeks. Endpoint definitions differ between documents: the registry's week 48 outcome defines clinical response as a reduction in Mayo score of at least 3 points, while its week 48 continuation criterion and the publication use at least 2 points; the registry adds an at least 1-point decrease in stool frequency subscore to the clinical remission definition. At week 48, 177 of 217 participants had clinical response in the publication and the posted results, and the Form 20-F reports 178 (82%). The registry's detailed description states a 48-week treatment period and its arm description states 96 weeks. Echocardiography was added by amendment after enrollment was complete, without drug-free baseline measurements. Participants were enrolled at 69 centers in 14 countries in Europe and Canada, race and ethnicity were not collected, and 10 participants discontinued for “Other reason (e.g., Ukraine Crisis)”. The protocol planned IBDQ assessment at week 24 and week 48, and no IBDQ results were located in the publication or the posted results. Abivax personnel designed the trial with the principal academic investigators, and Abivax analyzed the data.

ABX464-101

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Allocation“Randomized”
Interventional model“Parallel Assignment”
Interventional model description“Double-blind, placebo-controlled, randomized study”
Masking description“Double-Blind Treatment”
Primary purpose“Treatment”
Phase“Phase 2”
Enrollment (actual)“32”
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the posted results
AnalysisABX464Placebo
Baseline and safety analysis“23”“9”
Efficacy outcomes (total Mayo score, partial Mayo score, fecal calprotectin)“20”“9”
Description of analysis sets
Statistical tests in the posted results
OutcomeMethod
Treatment-emergent adverse events“Chi-squared”
Clinical remission“Chi-squared”
Fecal calprotectin“ANCOVA”
Total Mayo score“ANCOVA”
Partial Mayo score“ANCOVA”
Results
Participant disposition
Participant flow in the posted results
MilestoneABX464Placebo
Started“23”“9”
Completed“21”“9”
Not completed“2”“0”
Reason not completed: adverse event“1”“0”
Reason not completed: withdrawal by subject“1”“0”
Baseline characteristics
Age, sex, and race in the posted results
CharacteristicABX464 (N=23)Placebo (N=9)Total (N=32)
Age between 18 and 65 years“19”“9”“28”
Age 65 years or older“4”“0”“4”
Female“11”“1”“12”
Male“12”“8”“20”
White“23”“9”“32”
Baseline disease activity, disease duration, and prior advanced therapy

No evidence found.

Efficacy results
Clinical remission at week 8 in the posted results, with arm titles as the record lists them
FieldFirst arm listedSecond arm listed
Arm/group title“ABX464 Matching Placebo Treatment Arm”“ABX464 Treatment Arm”
Overall number of participants analyzed“20”“9”
Participants in clinical remission“7”“1”
Mayo score change and fecal calprotectin at week 8 in the posted results
OutcomeABX464 (n=20)Placebo (n=9)
Change from baseline in total Mayo score, mean (SD)“-4.6(2.8)”“-2.1(2.5)”
Change from baseline in partial Mayo score, mean (SD)“-3.9(2.2)”“-1.8(2.0)”
Participants with fecal calprotectin above 50 µg/g“15”“8”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Participants with treatment-emergent adverse events (primary outcome)
MeasureABX464Placebo
Overall number of participants analyzed“23”“9”
Participants with treatment-emergent adverse events“18”“5”
Time frame“Week 8”“Week 8”
Deaths, serious adverse events, and other adverse events in the posted results
Measure, affected / at risk (%)ABX464Placebo
All-cause mortality“0/23 (0.00%)”“0/9 (0.00%)”
Serious adverse events, total“0/23 (0.00%)”“1/9 (11.11%)”
Nephrolithiasis left side (serious)“0/23 (0.00%)”“1/9 (11.11%)”
Other (not including serious) adverse events, total“18/23 (78.26%)”“5/9 (55.56%)”
Other adverse events in at least two participants of either group
Study limitations
Summary

ABX464-101 was a randomized, double-blind, placebo-controlled phase 2a study in which 32 participants with moderately to severely active ulcerative colitis were randomized 2:1 to obefazimod 50 mg (23 participants) or placebo (9 participants) once daily for 8 weeks, at sites in six European countries. The registered primary endpoint was the number of participants with treatment-emergent adverse events; clinical remission by the total Mayo score at week 8 was registered as an outcome described as the “primary efficacy endpoint”. Efficacy was analyzed in participants without major protocol deviations who completed day 56 (20 receiving obefazimod and 9 receiving placebo), and the sponsor reported that 29 of the 32 participants “completed the study per protocol”. The planned sample size, stated in the ABX464-102 protocol, was a maximum of 30 participants, and no power calculation was located. Clinical remission at week 8 was reported as 35.0% with obefazimod and 11.1% with placebo, a difference the sponsor reported as not significant. The posted record lists the arm titles of the clinical remission outcome in the reverse order of the other outcomes, so its arm labels do not match its participant counts. The posted results analyze the change in partial and total Mayo scores by ANCOVA, whereas a 2019 press release reports p=0.029 for both, naming a likelihood ratio chi-square test for the partial Mayo score, and the 2018 topline release reports p<0.03 for the total Mayo score. Placebo clinical response is given as 33.0% in the ABX464-102 protocol and 33.3% in a 2021 press release. The sponsor describes the study drug as a tablet, and the posted record as a capsule. All 32 participants were White. Baseline disease activity, disease duration, and prior advanced therapy exposure were not reported in the readable sources, because the protocol and statistical analysis plan posted on ClinicalTrials.gov are image-only scans. No health-related quality of life results were located.

ABX464-102

Objective
Location and study date
Region of enrollment in the posted results
CountryParticipants
Belgium“3”
Poland“10”
Hungary“9”
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Allocation“N/A”
Interventional model“Single Group Assignment”
Interventional model description“open-label, follow-up study”
Masking“None (Open Label)”
Phase“Phase 2”
Enrollment (actual)“22”
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled and analyzed in the posted results
MeasureQuoted record
Enrollment (actual)“22”
Overall number of baseline participants“22”
Overall number of participants analyzed, each outcome“22”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MilestoneABX464 50 mg
Started“22”
Completed“11”
Not completed“11”
Baseline characteristics
Demographics in the posted results
CharacteristicABX464 50 mg (N=22)
Age, years, mean (SD)“42.4(14.3)”
Female“9”
Male“13”
White“22”
Efficacy results
Month 48 outcomes with non-responder imputation in the posted results
Outcome (N=22)Quoted record
Participants with clinical response“11”
Participants with clinical remission“9”
Participants with endoscopic improvement“9”
Participants with endoscopic remission“6”
Change in total Mayo score, mean (SD)“-3.0(3.4)”
Change in partial Mayo score, mean (SD)“-2.2(2.4)”
Change in fecal calprotectin, µg/g, mean (SD)“-299.69(472.28)”
Change in CRP, mg/L, mean (SD)“2.29(4.82)”
Change in ESR, mm/hour, mean (SD)“2.90(8.62)”
Ulcerative colitis worsening reported as an adverse event (post hoc)
MeasureQuoted record
Overall number of participants analyzed“22”
Participants with UC worsening“7”
Health-related quality of life and patient-reported outcomes
SF-36 component scores at up to 24 months in the posted results
Outcome (N=22, non-responder imputation)Change from day 0, mean (SD)
SF-36 physical component“4.82(4.23)”
SF-36 mental component“6.38(3.40)”
Safety results
Adverse event counts in the posted results
Outcome (N=22)Events
Treatment-emergent adverse events“145”
Treatment-emergent serious adverse events“3”
Treatment-emergent adverse events of special interest“15”
Adverse events leading to investigational product discontinuation“1”
Specific laboratory abnormalities, first 12 months“17”
Deaths and serious adverse events in the posted results
MeasureAffected / at risk (%)
All-cause mortality“0/22 (0.00%)”
Serious adverse events, total“3/22 (13.64%)”
Myocardial infarction“1/22 (4.55%)”
Enteropathic spondylitis“1/22 (4.55%)”
Benign ovarian tumor“1/22 (4.55%)”
Other adverse events in at least 3 participants
EventAffected / at risk (%)
Other (not including serious) adverse events, total“20/22 (90.91%)”
Colitis ulcerative“7/22 (31.82%)”
Abdominal pain“5/22 (22.73%)”
Nasopharyngitis“5/22 (22.73%)”
Diarrhoea“4/22 (18.18%)”
Vomiting“3/22 (13.64%)”
Headache“3/22 (13.64%)”
Study limitations
Summary

ABX464-102 was a single-group, open-label extension without a control group, in which 22 participants who completed ABX464-101 (15 previously assigned to obefazimod and 7 to placebo) received obefazimod 50 mg once daily, at sites in Belgium, Hungary, and Poland (3, 9, and 10 participants). Enrollment was based on participant willingness and investigator judgement, and the protocol set no sample size beyond a “Maximum 30 subjects”. The planned treatment period was 12 months in a 2018 press release, 24 months after a data safety monitoring board recommendation reported in 2019, and 48 months in the 2022 protocol. The primary endpoint was the number of treatment-emergent adverse events; efficacy results were to be “presented descriptively”. Eleven of 22 participants completed the study. Interim efficacy was reported among participants with an endoscopy at each timepoint (12 of 16 in clinical remission at month 12, 11 of 16 at month 24, and 11 of 13 at month 36); endoscopies were read locally at month 12 and centrally at month 24. In the posted non-responder imputation analysis, 9 of 22 participants were in clinical remission at month 48. The statistical analysis plan defines clinical response by the modified Mayo score, and the posted outcome description defines it by the total Mayo score. Seven of 22 participants had ulcerative colitis worsening reported as an adverse event. SF-36 was assessed only to month 24, and the echocardiography endpoints were moved to a separate report that was not located. All 22 participants were White.

ABX464-108

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Allocation“N/A”
Interventional model“Single Group Assignment”
Interventional model description“Open Label Follow-up Study”
Masking“None (Open Label)”
Phase“Phase 2”
Enrollment (estimated)“203”
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the congress presentation
AnalysisQuoted record
Safety, all participants“n = 130”
Week 144 completers“n=104”
Week 144 completers naive to advanced therapy inadequate response“57”
Week 144 completers with prior advanced therapy inadequate response“47”
Description of analysis sets
Results
Participant disposition
Participants at each timepoint in the program schema
TimepointQuoted record
Week 48“n= 114”
Week 96“n=107”
Completed week 144“n=104”
Baseline characteristics
Characteristics at the start of the 25 mg dose among week 144 completers
CharacteristicWeek 144 completers (n=104)
Age, years, mean (SD)“45.4 (12.74)”
Male, n (%)“65 (62.5)”
UC duration, years, mean (SD)“11.2 (7.02)”
Modified Mayo score 0 to 4, n (%)“104 (100)”
C-reactive protein, mg/L, median“2.2”
Fecal calprotectin, µg/g, median“57.0”
Concomitant corticosteroids, n (%)“6 (5.8)”
Concomitant 5-ASA, n (%)“79 (76.0)”
Prior refractoriness to biologics, n (%)“49 (47.1)”
Primary non-response, n (%)“19 (38.8)”
Loss of response, n (%)“30 (61.2)”
Efficacy results
Efficacy endpoints among week 144 completers
Endpoint (n=104)BaselineWeek 48Week 96Week 144
Clinical remission“91%”“85%”“85%”“85%”
Symptomatic remission“92%”“90%”“88%”“90%”
Endoscopic improvement“99%”“92%”“93%”“92%”
Endoscopic remission“66%”“66%”“72%”“72%”
Efficacy endpoints among week 144 completers by prior advanced therapy inadequate response
Endpoint and subgroupBaselineWeek 48Week 96Week 144
Clinical remission, AT-IR naive (N=57)“97%”“91%”“88%”“90%”
Clinical remission, prior AT-IR (N=47)“85%”“77%”“80%”“79%”
Symptomatic remission, AT-IR naive (N=57)“97%”“97%”“91%”“95%”
Symptomatic remission, prior AT-IR (N=47)“87%”“83%”“85%”“85%”
Endoscopic improvement, AT-IR naive (N=57)“100%”“93%”“95%”“95%”
Endoscopic improvement, prior AT-IR (N=47)“98%”“92%”“91%”“89%”
Endoscopic remission, AT-IR naive (N=57)“84%”“77%”“84%”“81%”
Endoscopic remission, prior AT-IR (N=47)“45%”“53%”“57%”“62%”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events in all 130 participants
EventN (%) [IR/100 PY]
Any TEAE“96 (73.8) [87.9]”
TEAE leading to discontinuation“9 (6.9) [4.25]”
Serious TEAE“8 (6.2) [3.86]”
Ulcerative colitis“15 (11.5) [7.3]”
Nasopharyngitis“11 (8.5) [5.4]”
Upper respiratory tract infection“10 (7.7) [4.9]”
COVID-19“11 (8.5) [5.4]”
Hypertension“7 (5.4) [3.4]”
Diarrhea“5 (3.8) [2.4]”
Arthralgia“5 (3.8) [2.4]”
Gastroenteritis“4 (3.1) [1.9]”
Non-melanoma skin cancer“1 (0.8) [0.5]”
Study limitations
Summary

ABX464-108 (Study 108) is an ongoing single-group, open-label extension without a control group, in which participants who completed the phase 2a (ABX464-102) or phase 2b (ABX464-104) open-label maintenance studies on obefazimod 50 mg, and who had a Mayo endoscopic subscore of 0 or 1 and a rectal bleeding subscore of 0, received obefazimod 25 mg once daily. Entry selected participants already in endoscopic improvement after 2 to 4 years of treatment: of 174 who completed the earlier studies, 138 were eligible and 130 were treated, and 89% (116/130) were in clinical remission at study baseline. The study has no randomized comparison of 25 mg with continued 50 mg. Results come from an interim analysis presented at a congress and in a press release (January 5, 2026 cutoff; February 13, 2026 data transfer); no peer-reviewed report or registry results exist, and primary completion is estimated for March 2028. Clinical remission by non-responder imputation was 73%, 69%, and 68% at weeks 48, 96, and 144. The baseline characteristics and the subgroup analyses by prior advanced therapy inadequate response were reported only for the 104 participants who completed week 144, among whom clinical remission was 84% to 85% in the as-observed analysis. Sources state the treatment period differently: a maximum of 54 months in the registry summary, 78 months in the registry outcome time frame and the poster, and up to five additional years in the press release. The number completing week 48 is 113 in the poster and 114 on a presentation slide, and the number completing the phase 2a extension is 10 in the poster and 11 in the posted ABX464-102 results. The safety table excludes laboratory findings. No health-related quality of life results were located.

ABX464-906

Objective
Location and study date
Trial dates and status in the EU register
Study design
Eligibility criteria
Participant type, age, and sex in the EU register
Treatment
Study outcomes
Rationale for using rosuvastatin pharmacokinetics as the study endpoint

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results

No evidence found.

Study limitations
Summary

ABX464-906 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (13 June 2024 to 20 February 2025), one site in France, and 24 planned healthy volunteers aged 18 to 64 years; the 20-F reports two drug-drug interaction trials with 24 and 36 enrolled healthy volunteers. The objectives, endpoints, doses, and eligibility criteria are not public, and the summary of results is deferred under the rules for category 1 trials until 20 August 2027. The register limits the population to healthy men. No pharmacokinetic or safety result has been published.

ABX464-910

Objective
Location and study date
Trial dates and status in the EU register
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using combined oral contraceptive pharmacokinetics as the study endpoint

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results

No evidence found.

Study limitations
Summary

ABX464-910 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (10 October 2023 to 31 August 2024), one site in Belgium, and 36 planned healthy women of childbearing potential aged 18 to 64 years. The doses, sampling schedule, endpoints, and the hormone measured are not public, and the summary of results is deferred until 28 February 2027. The 20-F states that the two drug-drug interaction trials were completed in 2025, whereas the register gives 31 August 2024 as the end of this trial. No pharmacokinetic or safety result has been published, so the effect of obefazimod on contraceptive exposure is unknown from public sources.

ABX464-902

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start (actual)“2020-12-17”
Primary completion (actual)“2021-05-18”
Results reporting dates in the registry record
FieldRegistry entry
Results first submitted“2022-05-06”
Results first posted“2026-11-09”
Other study ID numbers“ABX464-902”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using caffeine and Obefazimod cmax and AUC as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Participant flow in the registry results
MilestonePart APart B
Started“24”“35”
Completed“24”“34”
Withdrawal by subject“0”“1”
Baseline characteristics
Age and sex by study part
Efficacy results
Part A: caffeine exposure with and without obefazimod (PK analysis set, 22 participants)
Measure, mean (standard deviation)Day 1, caffeine aloneDay 4, caffeine and ABX464Day 17, caffeine and ABX464
Caffeine Cmax, ng/mL“931(285)”“930(278)”“564(242)”
Caffeine AUC, h*ng/mL“7420(4760)”“5460(2740)”“1560(719)”
Part B: obefazimod exposure with and without fluvoxamine (PK analysis set, 25 participants)
Measure, mean (standard deviation)Day 1, ABX464 aloneDay 11, ABX464 and fluvoxamine
ABX464 Cmax, ng/mL“23.2(12.5)”“33.4(19.0)”
ABX464 AUC, h*ng/mL“55.2(25.7)”“73.0(34.2)”
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Adverse events, serious adverse events, and deaths
MeasurePart A overallPart B overall
Participants with any other (nonserious) adverse event“16/24 (66.67%)”“30/35 (85.71%)”
Participants with a serious adverse event“0/24 (0.00%)”“0/35 (0.00%)”
Most frequent adverse events by study part
Study limitations
Summary

ABX464-902 enrolled 59 healthy adults in the United Kingdom (24 in Part A and 35 in Part B) and has no peer-reviewed publication. The registry results, first submitted in May 2022 and posted in November 2026, give means and standard deviations only. The protocol specified geometric least squares mean ratios with 90% confidence intervals, and neither the registry nor any other public source reports them. In Part A, the posted mean caffeine AUC was 7420 hng/mL on Day 1 alone and 1560 hng/mL on Day 17 after 14 days of obefazimod, and mean Cmax was 931 and 564 ng/mL; the HRA plain-language summary states that caffeine levels “remained similar in both the presence and absence of ABX464”, and the registry gives no analysis that reconciles the two. In Part B, mean obefazimod Cmax and AUC were higher with fluvoxamine (33.4 against 23.2 ng/mL and 73.0 against 55.2 h*ng/mL), and the HRA summary states that obefazimod “may be metabolised in the same pathway as fluvoxamine”. Nine of 35 Part B participants were excluded from the pharmacokinetic analysis for vomiting and one for early withdrawal; the registry states that these exclusions “did not impact on the overall evaluation of the study objectives”. No metabolite (ABX464-N-glucuronide) result is posted, Part B used single 50 mg doses of obefazimod, and race and ethnicity were not collected.

ABX464-908

Objective
Location and study date
Trial dates and status in the EU register
Study design
Eligibility criteria
Participant type and age in the EU register
Treatment
Study outcomes
Rationale for using Obefazimod pharmacokinetics in hepatic impairment as the study endpoint

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results

No evidence found.

Study limitations
Summary

ABX464-908 has only an EU register record and a sentence in the Form 20-F. The register gives the title, the dates (9 October 2023 to 11 September 2024), one site in Germany, and 32 planned participants; the 20-F reports 30 enrolled participants with mild or moderate hepatic impairment or matched normal liver function. The 20-F states that the trial was completed in 2025, whereas the register gives 11 September 2024 as its end. The classification method for hepatic impairment, the dose, the number per group, and the endpoints are not public, severe hepatic impairment was not studied, and the summary of results is deferred until 11 March 2027. The 20-F describes the results only as “supportive data” for the NDA, so no exposure ratio or safety result is available to inform dosing in hepatic impairment.

ABX464-907

Objective
Location and study date
Trial dates and status in the EU register
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using Obefazimod pharmacokinetics in renal impairment as the study endpoint

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results

No evidence found.

Study limitations
Summary

ABX464-907 has only an EU register record. The register gives the title, the dates (9 September 2024 to 14 October 2025), one site in Germany, and 48 planned participants, who include patients and healthy volunteers aged 18 years or older. The Form 20-F does not name this trial among the completed Phase 1 trials. The categories of renal impairment, the dose, the number per group, the inclusion of participants on dialysis, and the endpoints are not public, and the summary of results is deferred until 14 April 2028. No exposure or safety result is available to inform dosing in renal impairment.

ABX464-FE-001

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start“2014-09”
Primary completion (actual)“2015-06”
Other study ID numbers“ABX464-FE-001”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using single-dose AUC and cmax under fed and fasted conditions as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Study limitations
Summary

ABX464-FE-001 enrolled 48 healthy men in Mauritius in 2014 and 2015, 24 per group; the registry described 40 healthy Caucasian men. The repeated-dose group received 50 mg every 3 days, a schedule the authors chose for safety reasons, and compared fed and fasted conditions in a parallel design. The authors state that the study “does have a number of intrinsic limitations”: women were excluded, no age effects could be analyzed, and the terminal elimination rate constant after a single dose could be determined in only 17 participants fasted and 13 fed. One participant without quantifiable fasted concentrations was excluded from the pharmacokinetic analysis, and four authors are Abivax employees.

ABX464-001

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start“2014-03”
Primary completion (actual)“2014-07”
Other study ID numbers“ABX464-001”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using the percentage of participants with at least one adverse event as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
FieldRegistry entry
Enrollment (actual)“24”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Study limitations
Summary

ABX464-001 gave a single oral dose of 50, 100, 150, or 200 mg after overnight fasting to 24 healthy men, 6 per dose group. It had no placebo group and no repeated dosing, enrolled men only, and all doses were given fasted. The full article is closed access, and the abstract gives no numerical pharmacokinetic parameters by dose, no adverse event counts, and no dose-proportionality analysis beyond stating that the metabolite-to-parent ratio “was consistent across the complete dose range”. The registry record posts no results, and four of eight authors list Abivax as their affiliation.